When was BTG International founded?

BTG International was founded in 1948 and raised its 1st funding round 60 years after it was founded.

Where is BTG International located?

BTG International is headquartered in London, United Kingdom.

Who is the current CEO of BTG International?

Dame Louise Makin of BTG International.

How many employees does BTG International have?

As of May 31, 2026, the latest employee count at BTG International is 651.

Is BTG International a funded company?

BTG International is a funded company, having raised an undisclosed amount across 4 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on May 15, 2008.

When was the latest funding round of BTG International?

BTG International's latest funding was a $***** Post IPO round on Jan 28, 2011, with participation from 0 investor. Its primary sector is Cardiac and Vascular Disorders. Globally, the Cardiac and Vascular Disorders sector has seen $1.49B in funding in 2026 to date.

Where does BTG International rank among its competitors?

BTG International ranks 4th amongst 25 active competitors, of which 7 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Aria CV, which secured $1.38M in Aug, 2025.

Who are the top competitors of BTG International?

BTG International's top competitors include Penumbra, Pulnovo Medical and SoniVie. Among them, Aria CV secured the most recent funding round in August, 2025.

BTG International - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

BTG develops therapeutic agents to treat neurological, varicose veins and other disorders. The company offers products under three business segments including Interventional Medicine that deals with interventional oncology products (bead products, TheraSphere, treatment of liver cancer); interventional vascular products (EkoSonic, used for treatment of blood clots, Varithena, treatment of varicose veins); and interventional pulmonology products (PneumRx Coil for advanced emphysema). It also offers antidote products like CroFab, used for the treatment of envenomations from the copperhead snake, DigiFab, for digoxin toxicity, Voraxaze for high-dose methotrexate toxicity, and Vistogar, used for the treatment of side effects of overexposure to the chemotherapeutic 5-fluorouracil among others.

Key Metrics

Founded Year

1948

Location

London, United Kingdom

Stage

Acquired

Latest Funding Round

Post IPO, Jan 28, 2011, $*****

Investors

Novo Holdings & 2 more

Ranked

4^th among 25 active competitors

Employee Count

651 as on May 31, 2026

Investment & Acquisitions

Veran Medical & 10 more

Similar Companies

Penumbra & 27 more

Exit Details

Acquired by Boston Scientific (Nov 20, 2018)

View BTG International's full profile

BTG International is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Btg International Limited CIN: 2664412 , Germany, Active	Nov 13, 1991	-	2 (As on Dec 31, 2020)

BTG International got acquired by Boston Scientific on Nov 20, 2018.

Click here to take a look at BTG International's acquisition in detail

BTG International has raised funding over 4 rounds. Its first funding round was on May 15, 2008. BTG International has 3 institutional investors.

Here is the list of recent funding rounds of BTG International:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 28, 2011	9181455	Post IPO	4414619	9113318	3745574	6551032
Jan 01, 2011	7077182	Grant (prize money)	7234017	1064711	2908933	HHS
Jun 01, 2010	7281119	Grant (prize money)	8255328	8460082	1237961	HHS

Access funding benchmarks and valuations. Sign up today!

View details of BTG International's funding rounds and investors

BTG International's employee count trend

BTG International has 651 employees as of May 26. Here is BTG International's employee count trend over the years:

Employee count trend for BTG International

Uncover BTG International's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of BTG International include Penumbra, Pulnovo Medical and SoniVie. Here is the list of Top 10 competitors of BTG International, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Penumbra 2004, Alameda (United States), Acquired	Developer of medical devices for neurovascular and peripheral thrombectomy	$121K	Novo Holdings, The Angels’ Forum & 4 others	63/100
2nd	Pulnovo Medical 2013, Wuxi (China), Series C	Developer of a medical device for the treatment of pulmonary hypertension	$115M	LAV Asset Management, Qiming Venture Partners ... & 8 others	54/100
3rd	SoniVie 2014, Rosh Haayin (Israel), Acquired	Developer of denervation catheter for the treatment of pulmonary hypertension	$62.5M	Andera Partners, Accelmed & 6 others	51/100
4th	BTG International 1948, London (United Kingdom), Acquired	Developer of therapeutics for oncology, pulmonology, hematology and anti-venom	-	Novo Holdings, Blue HK Investments & 1 others	48/100
5th	Aria CV 2010, Saint Paul (United States), Series B	Device for pulmonary hypertension	$45M	Xeraya Capital, CHV & 10 others	47/100
6th	Adient Medical 2012, Pearland (United States), Series B	Provider of bio-absorbable medical devices	$19.4M	Cordis, Broadview Ventures & 8 others	41/100
7th	Bellerophon Therapeutics 2014, Hampton (United States), Public	Device for treatment of pulmonary hypertension	-	Venrock, New Mountain Capital & 6 others	37/100
8th	BiO2 Medical 2006, San Antonio (United States), Series D	Innovating medical devices and biotechnology solutions for critical care and research	$56.3M	Remeditex, Targeted Technology & 2 others	36/100
9th	Angiodynamics 1988, Latham (United States), Public	Singapore real estate insights: new condos, rental market, and urban planning	-	Saints Capital, Forbion	36/100
10th	VentriFlo 2001, Pelham (United States), Series A	Developing pulsatile blood pumps for superior cardiopulmonary support and improved patient outcomes	$10M	-	33/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on BTG International's competitors? Click here to see the top ones

BTG International has made 4 investments in companies including Veran Medical and Xention. BTG International has also acquired 7 companies including Novate Medical and Novate Medical.

Here is the list of investments & acquisitions:

Filter this list

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Nov 14, 2018	Investments	Veran Medical	2005	St. Louis (United States)
Sep 07, 2018	Acquisition	Novate Medical	2010	New Orleans (United States)
Sep 07, 2018	Acquisition	Novate Medical	2006	Galway (Ireland)